<DOC>
	<DOCNO>NCT01645306</DOCNO>
	<brief_summary>Patients suffer symptomatic carotid artery stenosis , transient ischemic attack ( TIAs ) , amaurosis fugax stroke receive either Revacept ( single dose ) plus antiplatelet monotherapy monotherapy alone . Patients receive single dose trial medication intravenous infusion 20 minute . Patients follow one three day treatment , 3 month telephone interview 12 month .</brief_summary>
	<brief_title>Revacept Symptomatic Carotid Stenosis ( Revacept/CS/02 )</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Ischemic Attack , Transient</mesh_term>
	<mesh_term>Carotid Stenosis</mesh_term>
	<mesh_term>Blindness</mesh_term>
	<mesh_term>Amaurosis Fugax</mesh_term>
	<mesh_term>Mannitol</mesh_term>
	<criteria>1 . Signed write informed consent 2 . Target population Diagnosis : Extracranial carotid artery stenosis ( diagnosed vascular duplex ultrasound peak flow angiography ) Lesions â‰¥ 50 % stenosis accord European Carotid Surgery Trial ( ECST ) criterion TIA , amaurosis fugax stroke within last 30 day Age sex : Men woman age &gt; 18 year Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study 4 week receive investigational product manner risk pregnancy minimise . 1 . Sex reproductive Status : WOCBP unwilling unable use acceptable method avoid pregnancy 4 week receive investigational product . Women pregnant breastfeed Women positive pregnancy test enrollment prior investigational product administration . 2 . Target disease exception NIHSS score &gt; 18 Recent intracerebral haemorrhage Xray compute tomography ( CT ) nuclear magnetic resonance ( NMR ) Cardiac cause embolisation ( atrial fibrillation cardiac source e.g . artificial heart valve ) 3 . Medical history concurrent disease History hypersensitivity , contraindication serious adverse reaction inhibitor platelet aggregation , hypersensitivity relate drug ( crossallergy ) excipients study drug History evidence thrombocytopenia ( &lt; 30.000/ul ) , bleed diathesis coagulopathy ( pathological international normalise ratio ( INR ) activate partial thromboplastin time ( aPTT ) ) Thrombolysis within last 48 hour Relevant haemorrhagic transformation determine CT , NMR anamnesis Oral anticoagulation dual antiplatelet therapy aspirin clopidogrel P2Y inhibitor screen ( 3 day dipyridamole extend release ; 8 hour tirofiban/Aggrastat ) Sustained hypertension ( systolic BP &gt; 179 mmHg diastolic BP &gt; 109 mmHg ) History severe systemic disease terminal carcinoma , renal failure ( current creatinine &gt; 200 umol/l ) , cirrhosis , severe dementia , psychosis Current severe liver dysfunction ( transaminase level great 5fold upper normal range limit ) Active autoimmune disorder systemic lupus erythematosus , rheumatoid arthritis , vasculitis glomerulonephritis Known atrial fibrillation clinically significant ECG abnormality ( present )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>